Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Issues / 2015 / Dec / Multitalented Marker
Hematology Hematology Point of care testing

Multitalented Marker

Cardiac troponin can be used as an independent early indicator of end-stage kidney disease, and death, new study suggests

By Roisin McGuigan 12/18/2015 1 min read

Share

Cardiac troponin can be used as an independent early indicator of end-stage kidney disease, and death, new study suggests

Cardiac troponin T (cTnT) is an extremely valuable biomarker, most well-known for its use in detecting damage to the heart muscle. But the protein can also come in useful in a range of conditions that may have a link to cardiac injury – and a recent study has shown for the first time that cTnT can independently provide prognostic information on end-stage renal disease (ESRD) and mortality in people with hypertension (1). The study involved 3,050 individuals with a family history of hypertension, and looked at both African Americans and Caucasians – an important point, as previous studies have found that African Americans have much higher kidney disease rates compared with Caucasians (2). The researchers found that regardless of race, or baseline kidney function, cTnT accurately indicated an increased risk of kidney failure and death (1).

In study participants with elevated cTnT, the cumulative estimated risk of death at 10 years was 47 percent, compared with 7.3 percent among those with normal cTnT levels – and incidence of ESRD was 27 percent, compared with 1.3 percent in those without elevated cTnT levels. “This study demonstrates to physicians everywhere that we are getting closer to accurately predicting future disease and death by examining this one marker. This is important, because, as with many diseases, accurate, early detection means we can more quickly recognize and efficiently treat the disease before it fully manifests – potentially improving a patient’s quality and quantity of life,” says co-author of the paper, LaTonya Hickson. Despite these promising findings, further study is needed, as abnormal cTnT levels are not prevalent enough in the group studied to significantly improve risk prediction. However, the authors note that it may be possible to identify subgroups of patients who could potentially benefit from this type of screening.

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. LJ Hickson et al., “Troponin T as a predictor of end-stage renal disease and all-cause death  in African Americans and whites from hypertensive families”, Mayo Clin Proc, 90, 1482–1491 (2015). PMID: 26494378. National Institute of Diabetes and Digestive and Kidney Diseases, “Race, Ethnicity and  Kidney Disease”, (2014). Available at: http://1.usa.gov/1MRXU0g. Accessed November 9, 2015.

About the Author(s)

Roisin McGuigan

I have an extensive academic background in the life sciences, having studied forensic biology and human medical genetics in my time at Strathclyde and Glasgow Universities. My research, data presentation and bioinformatics skills plus my ‘wet lab’ experience have been a superb grounding for my role as an Associate Editor at Texere Publishing. The job allows me to utilize my hard-learned academic skills and experience in my current position within an exciting and contemporary publishing company.

More Articles by Roisin McGuigan

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

Case of the Month
Hematology
Case of the Month

January 11, 2022

1 min read

Enriching Our Understanding of Multiple Myeloma
Hematology
Enriching Our Understanding of Multiple Myeloma

February 9, 2022

3 min read

Career Snapshots with Robert Dunn
Hematology
Career Snapshots with Robert Dunn

May 25, 2022

1 min read

Michael Schubert interviews Robert Dunn on working as a biomedical scientist in cytogenetics

A Moment in the Sun
Hematology
A Moment in the Sun

June 23, 2022

4 min read

The decades-long fight for T cells to earn their place in the limelight

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.